Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
Top Cited Papers
- 15 March 2003
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 370 (3) , 1097-1109
- https://doi.org/10.1042/bj20021371
Abstract
The binding of advanced glycation end-products (AGE) to the receptor for AGE (RAGE) is known to deteriorate various cell functions and is implicated in the pathogenesis of diabetic vascular complications. In the present study, we show that the cellular constituents of small vessels, endothelial cells (EC) and pericytes express novel splice variants of RAGE mRNA coding for the isoforms that lack the N-terminal V-type immunoglobulin-like domain (N-truncated) or the C-terminal transmembrane domain (C-truncated), as well as the known full-length mRNA. The ratio of the expression of the three variants was different between EC and pericytes; the content of the C-truncated form was highest in EC, whereas the full-length form was the most abundant in pericytes. Transfection experiments with COS-7 cells demonstrated that those variant mRNAs were translated into proteins as deduced; C-truncated RAGE was efficiently secreted into the culture media, and N-truncated RAGE was located mainly on the plasma membrane. The three isoforms were also detected in primary cultured human EC and pericytes. Further, full-length and C-truncated forms of RAGE bound to an AGE-conjugated column, whereas N-truncated RAGE did not. The AGE induction of extracellular-signal-related kinase phosphorylation and vascular endothelial growth factor in EC and of the growth and cord-like structure formation of EC was abolished completely by C-truncated RAGE, indicating that this endogenous secretory receptor (endogenous secretory RAGE) is cytoprotective against AGE. The results may contribute to our understanding of the molecular basis for the diversity of cellular responses to AGE and for individual variations in the susceptibility to diabetic vascular complications.Keywords
This publication has 42 references indexed in Scilit:
- Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling PathwaysJournal of Biological Chemistry, 1999
- Principles governing amino acid composition of integral membrane proteins: application to topology prediction 1 1Edited by J. ThorntonJournal of Molecular Biology, 1998
- Ribozyme Targeting of Receptor for Advanced Glycation End Products in Mouse Mesangial CellsBiochemical and Biophysical Research Communications, 1998
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin‐producing ability of endothelial cells through interactions with their receptorsFEBS Letters, 1996
- Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and PericytesJournal of Biological Chemistry, 1995
- Receptor-Mediated Toxicity to Pericytes of Advanced Glycosylation End Products: A Possible Mechanism of Pericyte Loss in Diabetic MicroangiopathyBiochemical and Biophysical Research Communications, 1995
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase FBiochemistry, 1985
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976